Vishesh Agrawal1, Thibaud P Coroller2, Ying Hou2, Stephanie W Lee2, John L Romano2, Elizabeth H Baldini1, Aileen B Chen1, David M Jackman3, David Kozono1, Scott J Swanson4, Jon O Wee4, Hugo J W L Aerts5, Raymond H Mak6. 1. Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. 2. Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA. 3. Harvard Medical School, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA. 4. Harvard Medical School, Boston, MA, USA; Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, MA, USA. 5. Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA. 6. Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: rmak@partners.org.
Abstract
OBJECTIVES: Accurate assessment of tumor response to chemoradiation has the potential to guide clinical decision-making regarding surgical resection and/or dose escalation for patients. Early assessment has implications for Optimal local therapy for operable locally advanced non-small cell lung cancer (LA-NSCLC) is controversial. This study evaluated quantitative CT-based tumor measurements to predict pathologic response. MATERIALS AND METHODS: Patients with operable LA-NSCLC treated with chemoradiation followed by surgical resection were assessed. Tumor diameter and volume were quantified from CT imaging obtained prior to chemoradiation and post-chemoradiation prior to surgical resection. Univariate and multivariate logistic regression were used to determine association with the primary endpoint of pathologic complete response (pCR). Overall survival, locoregional recurrence, and distant metastasis were assessed as secondary endpoints. RESULTS: 101 LA-NSCLC patients were identified and treated with preoperative chemoradiation and surgical resection. The median RT dose was 54Gy (range, 46-70) and 98% of patients received concurrent chemoradiation as part of their preoperative treatment. Reduction of CT-defined tumor volume was associated with pCR (OR 1.06 [1.02-1.09], p=0.002) and LRR (HR 1.01 [1.00-1.02], p=0.048). Conventional response assessment determined by RECIST (p=0.213) was not associated with pCR or any secondary endpoints. CONCLUSION: CT-measured reductions in tumor volume after chemoradiation are associated with pCR and provide greater clinical information about tumor response than conventional response assessment (RECIST) or absolute tumor sizes or volumes. This study demonstrates that change in tumor volumes provides better radiologic-pathologic correlation and is thus an additional tool to assess tumor response following chemoradiation.
OBJECTIVES: Accurate assessment of tumor response to chemoradiation has the potential to guide clinical decision-making regarding surgical resection and/or dose escalation for patients. Early assessment has implications for Optimal local therapy for operable locally advanced non-small cell lung cancer (LA-NSCLC) is controversial. This study evaluated quantitative CT-based tumor measurements to predict pathologic response. MATERIALS AND METHODS:Patients with operable LA-NSCLC treated with chemoradiation followed by surgical resection were assessed. Tumor diameter and volume were quantified from CT imaging obtained prior to chemoradiation and post-chemoradiation prior to surgical resection. Univariate and multivariate logistic regression were used to determine association with the primary endpoint of pathologic complete response (pCR). Overall survival, locoregional recurrence, and distant metastasis were assessed as secondary endpoints. RESULTS: 101 LA-NSCLCpatients were identified and treated with preoperative chemoradiation and surgical resection. The median RT dose was 54Gy (range, 46-70) and 98% of patients received concurrent chemoradiation as part of their preoperative treatment. Reduction of CT-defined tumor volume was associated with pCR (OR 1.06 [1.02-1.09], p=0.002) and LRR (HR 1.01 [1.00-1.02], p=0.048). Conventional response assessment determined by RECIST (p=0.213) was not associated with pCR or any secondary endpoints. CONCLUSION: CT-measured reductions in tumor volume after chemoradiation are associated with pCR and provide greater clinical information about tumor response than conventional response assessment (RECIST) or absolute tumor sizes or volumes. This study demonstrates that change in tumor volumes provides better radiologic-pathologic correlation and is thus an additional tool to assess tumor response following chemoradiation.
Authors: Lukas Käsmann; Maximilian Niyazi; Oliver Blanck; Christian Baues; René Baumann; Sophie Dobiasch; Chukwuka Eze; Daniel Fleischmann; Tobias Gauer; Frank A Giordano; Yvonne Goy; Jan Hausmann; Christoph Henkenberens; David Kaul; Lisa Klook; David Krug; Matthias Mäurer; Cédric M Panje; Johannes Rosenbrock; Lisa Sautter; Daniela Schmitt; Christoph Süß; Alexander H Thieme; Maike Trommer-Nestler; Sonia Ziegler; Nadja Ebert; Daniel Medenwald; Christian Ostheimer Journal: Strahlenther Onkol Date: 2017-10-13 Impact factor: 3.621
Authors: Raymond H Mak; Michael G Endres; Jin H Paik; Rinat A Sergeev; Hugo Aerts; Christopher L Williams; Karim R Lakhani; Eva C Guinan Journal: JAMA Oncol Date: 2019-05-01 Impact factor: 31.777
Authors: Kevin X Liu; Kailan Sierra-Davidson; Kevin Tyan; Lawrence T Orlina; J Paul Marcoux; Benjamin H Kann; David E Kozono; Raymond H Mak; Abby White; Lisa Singer Journal: Radiother Oncol Date: 2021-10-22 Impact factor: 6.280
Authors: C Ostheimer; M Mäurer; N Ebert; D Schmitt; D Krug; R Baumann; C Henkenberens; F A Giordano; L Sautter; Guerra López; D F Fleischmann; M Niyazi; L Käsmann; D Kaul; A H Thieme; C Billiet; S Dobiasch; C R Arnold; M Oertel; J Haussmann; T Gauer; Y Goy; C Suess; S Ziegler; C M Panje; C Baues; M Trommer; T Skripcak; D Medenwald Journal: Strahlenther Onkol Date: 2021-01-07 Impact factor: 3.621
Authors: Michal R Tomaszewski; Shuxuan Fan; Alberto Garcia; Jin Qi; Youngchul Kim; Robert A Gatenby; Matthew B Schabath; William D Tap; Denise K Reinke; Rikesh J Makanji; Damon R Reed; Robert J Gillies Journal: Tomography Date: 2022-02-02